

Xavier Pdmj Verhelst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3735497/publications.pdf>

Version: 2024-02-01

79
papers

2,486
citations

249298

26
h-index

252626

46
g-index

81
all docs

81
docs citations

81
times ranked

4025
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	1.9	15
2	Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection. <i>Acta Clinica Belgica</i> , 2023, 78, 96-102.	0.5	2
3	Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 740-755.	2.4	19
4	Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1776-1783.e4.	2.4	11
5	Illness cognitions and health-related quality of life in liver transplant patients related to length of stay, comorbidities and complications. <i>Quality of Life Research</i> , 2022, 31, 2493-2504.	1.5	3
6	⁹⁰ Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. <i>Radiology</i> , 2022, 303, 699-710.	3.6	74
7	Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation. <i>Cancers</i> , 2022, 14, 2973.	1.7	3
8	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
9	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	1.8	76
10	Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. <i>Journal of Hepatology</i> , 2021, 74, 240-241.	1.8	12
11	NOX1 inhibition attenuates the development of a pro-tumorigenic environment in experimental hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 40.	3.5	13
12	Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models. <i>Oncotarget</i> , 2021, 12, 562-577.	0.8	11
13	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1514-1522.	0.2	14
14	The utility of biomarkers in prognosis assessment of patients with acute liver failure. <i>Hepatology Research</i> , 2021, 51, 750-757.	1.8	5
15	Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1. <i>United European Gastroenterology Journal</i> , 2021, 9, 662-671.	1.6	10
16	Focal eosinophilic infiltration of the liver, benign or malignant?. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04448.	0.2	2
17	Diagnostic and prognostic scoring systems for autoimmune hepatitis : a review. <i>Acta Gastro-Enterologica Belgica</i> , 2021, 84, 487-495.	0.4	6
18	The neurogliovascular unit in hepatic encephalopathy. <i>JHEP Reports</i> , 2021, 3, 100352.	2.6	22

#	ARTICLE	IF	CITATIONS
19	Serum Glycomics on Postoperative Day 7 Are Associated With Graft Loss Within 3 Months After Liver Transplantation Regardless of Early Allograft Dysfunction. <i>Transplantation</i> , 2021, 105, 2404-2410.	0.5	3
20	Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. <i>Gastroenterology</i> , 2020, 158, 95-110.	0.6	95
21	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
22	Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury. <i>Journal of Leukocyte Biology</i> , 2020, 107, 341-355.	1.5	21
23	Up to 50% of portal vein thrombosis remains undiagnosed until liver transplantation. <i>Clinical Transplantation</i> , 2020, 34, e14107.	0.8	6
24	Hepatitis C in two general practices in Flanders, Belgium: is there a need to reconsider current screening recommendations?. <i>Acta Clinica Belgica</i> , 2020, 76, 1-8.	0.5	2
25	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
26	Bariatric Surgery Patients Are at Risk for Alcoholic Liver Disease with Need for Liver Transplantation. <i>Obesity Surgery</i> , 2020, 30, 4659-4664.	1.1	15
27	Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2020, 72, 1701-1716.	3.6	27
28	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	1.8	47
29	Myeloid-specific IRE1 α deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154220.	1.5	19
30	Effect of isoform-specific HIF-1 β and HIF-2 β antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model. <i>Oncotarget</i> , 2020, 11, 4504-4520.	0.8	13
31	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
32	Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience. <i>European Respiratory Journal</i> , 2019, 53, 1801096.	3.1	16
33	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 992-999.	1.8	25
34	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	1.9	66
35	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
36	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	0.6	296

#	ARTICLE	IF	CITATIONS
37	Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis. Case Reports in Gastroenterology, 2019, 12, 597-601.	0.3	7
38	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology, 2019, 156, 96-107.e1.	0.6	82
39	Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 1087-1104.	3.6	82
40	Severe Hepatic and Pulmonary Involvement in Rendu-Osler-Weber Syndrome. Case Reports in Gastroenterology, 2018, 12, 13-18.	0.3	1
41	Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction. Gastroenterology, 2018, 154, 1361-1368.	0.6	13
42	Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium. Journal of Clinical Virology, 2018, 103, 8-11.	1.6	5
43	Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice. Hepatology, 2018, 68, 634-651.	3.6	39
44	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.2	64
45	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	3.6	55
46	Endoglycosidase S Enables a Highly Simplified Clinical Chemistry Procedure for Direct Assessment of Serum IgG Undergalactosylation in Chronic Inflammatory Disease. Molecular and Cellular Proteomics, 2018, 17, 2508-2517.	2.5	17
47	Refractory subacute steatohepatitis after biliopancreatic diversion. Hepatology, 2017, 66, 289-291.	3.6	12
48	Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. International Journal of Obesity, 2017, 41, 1207-1213.	1.6	40
49	Hepatitis E virus serology and PCR: does the methodology matter?. Archives of Virology, 2017, 162, 2625-2632.	0.9	15
50	A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis. Clinical Cancer Research, 2017, 23, 2750-2758.	3.2	31
51	Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. Cellular Immunology, 2017, 322, 74-83.	1.4	81
52	Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication. Liver International, 2017, 37, 748-756.	1.9	24
53	Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis. International Journal of Molecular Sciences, 2017, 18, 214.	1.8	24
54	Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form. International Journal of Molecular Sciences, 2016, 17, 1384.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 438.	1.1	3
56	Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 848-854.	0.7	25
57	Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 3419-3431.	2.4	50
58	Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 9.	1.1	26
59	The role of macrophages in obesity-driven chronic liver disease. <i>Journal of Leukocyte Biology</i> , 2016, 99, 693-698.	1.5	34
60	Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. <i>Obesity</i> , 2016, 24, 2544-2552.	1.5	23
61	Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 34988-35000.	0.8	22
62	Quality of life after liver transplantation: State of the art. <i>World Journal of Hepatology</i> , 2016, 8, 749.	0.8	50
63	Effect of prolyl hydroxylase domain 2 haplodeficiency on liver progenitor cell characteristics in early mouse hepatocarcinogenesis. <i>EXCLI Journal</i> , 2016, 15, 687-698.	0.5	6
64	Time-Dependent Effect of Hypoxia on Tumor Progression and Liver Progenitor Cell Markers in Primary Liver Tumors. <i>PLoS ONE</i> , 2015, 10, e0119555.	1.1	12
65	Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. <i>Liver International</i> , 2015, 35, 1646-1660.	1.9	81
66	Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy. <i>Hepatology International</i> , 2015, 9, 93-104.	1.9	58
67	Intramuscular hepatitis B immunoglobulins for reinfection control after liver transplantation: a cost-saving alternative. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 259-265.	0.6	2
68	Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome. <i>Liver International</i> , 2015, 35, 1499-1507.	1.9	23
69	Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure. <i>Oncotarget</i> , 2015, 6, 28011-28025.	0.8	36
70	Evaluation of the value of serum glycomics (GlycoCirrhoTest) for risk prediction of hepatocellular carcinoma in compensated cirrhosis. <i>Journal of Clinical Oncology</i> , 2015, 33, 4079-4079.	0.8	0
71	Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma. <i>Clinical Case Reports (discontinued)</i> , 2014, 2, 4-6.	0.2	5
72	Therapeutic effects of artesunate in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 861-870.	0.8	39

#	ARTICLE	IF	CITATIONS
73	Optimal use of corticosteroids in gastroenterology and hepatology. <i>Journal of Translational Internal Medicine</i> , 2014, 2, 53-58.	1.0	2
74	Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review. <i>Hepatology Research</i> , 2013, 43, 165-178.	1.8	24
75	Pathophysiology and Management of Post Resection Liver Failure. <i>Acta Chirurgica Belgica</i> , 2013, 113, 155-161.	0.2	7
76	Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 495-502.	0.8	46
77	The paradox of the unfolded protein response in cancer. <i>Anticancer Research</i> , 2013, 33, 4683-94.	0.5	132
78	Progressive multifocal leukoencephalopathy in liver transplant recipients: a case report and review of the literature. <i>Transplant International</i> , 2011, 24, e30-e34.	0.8	15
79	Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 494-499.	0.8	36